相关实验视频

Updated: May 15, 2025

Functional Assessment of Intestinal Motility and Gut Wall Inflammation in Rodents: Analyses in a Standardized Model of Intestinal Manipulation

Functional Assessment of Intestinal Motility and Gut Wall Inflammation in Rodents: Analyses in a Standardized Model of Intestinal Manipulation

Published on: September 11, 2012

在小鼠中通过和小分子RXFP4激动剂缓解洛佩拉胺诱导的便秘

Shiyu Yan¹, Yan Chen², Jiang Wang³

¹State Key Laboratory of Chemical Biology and The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, PR China; University of Chinese Academy of Sciences, Beijing 100049, PR China.

Biochemical pharmacology

|April 7, 2025

概括

用INSL5或DC591053等激动剂激活放松素/胰岛素类家族受体4 (RXFP4),可以有效治疗便秘. 这些治疗方法改善了小鼠的肠道运动和结肠健康,提供了一个新的治疗途径.

科学领域:

胃肠病学胃肠病学
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

便秘是一种普遍的胃肠道问题,由于副作用,有效治疗方法有限.
放松素/胰岛素类家族受体4 (RXFP4) 是管理肠道运动的潜在目标.

研究的目的:

为了研究RXFP4激动剂,INSL5和DC591053的治疗潜力,在洛佩拉胺诱导便秘的小鼠模型中.
评估这些激动剂对便参数,结肠过境和相关分子标记物的影响.

主要方法:

性 (INSL5) 和小分子 (DC591053) RXFP4激活剂给便秘的小鼠.
评估便中的水含量,便重量,结肠过渡时间和血清神经递质水平 (NO,5-HT,VIP).
结肠组织的组织学检查和基因表达的分析 (AQP3,TRPV1,CGRP).

主要成果:

无论是INSL5还是DC591053,都依赖于剂量增加了便中的水和体重,加速了便秘小鼠的结肠过渡.
治疗改善了结肠形态,并调节了关键便秘相关因素的表达.
对比分析表明,这两种激动剂之间的药理动力学特性具有相似的疗效,但存在潜在的差异.

结论:

通过INSL5或DC591053激活RXFP4,表明对便秘有显著的治疗效果.
RXFP4激动剂代表了对便秘管理的有前途的新疗法策略.
对不同RXFP4激动剂的特异性质进行进一步研究是有必要的.

关键词:

激进主义者的激进主义者结肠运动性结肠运动性便秘便秘便秘便秘 INSL5 在线阅读在RXFP4中使用RXFP4.

更多相关视频

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

A Mouse Model of Intestinal Partial Obstruction

A Mouse Model of Intestinal Partial Obstruction

Published on: March 5, 2018

相关概念视频

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...

Drugs Affecting GI Tract Motility: Other Laxatives

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...